Suzhou Fuente Pharmaceutical

Suzhou Fuente Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics. The company utilizes a proprietary platform integrating structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) to target high-value proteins in oncology and metabolic diseases. Its lead program, FDM-001, is a highly selective USP1 inhibitor that has entered clinical trials for the treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies. Fuente Pharmaceutical aims to build a robust pipeline of precision medicines by tackling challenging targets that were previously considered undruggable. The company is backed by prominent venture capital firms and operates out of the Suzhou BioBAY industrial park.